Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many bacterial beta-lactamase enzymes, thereby extending its spectrum of activity against beta-lactamase-producing bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia (including ventilator-associated pneumonia)
* Febrile neutropenia (empiric treatment)
## Adult Dosing
* **Standard Dose:** 3.375 grams (piperacillin 3 g / tazobactam 0.375 g) or 4.5 grams (piperacillin 4 g / tazobactam 0.5 g) intravenously every 6 or 8 hours.
* **Dosage Frequency:** Typically every 6 or 8 hours. For severe infections or in febrile neutropenia, a continuous infusion of 4.5 grams (piperacillin 4 g / tazobactam 0.5 g) over 4 hours has been used.
* **Maximum Dose:** Not explicitly defined, but doses of 4.5 grams every 6 hours are common. Higher doses may be considered in select severe infections at the discretion of the prescriber.
## Pediatric Dosing
* **Children < 12 years:** Dosing is typically based on piperacillin component and is usually 80-100 mg/kg/day (piperacillin equivalent) divided every 6 or 8 hours. The tazobactam component is generally dosed at a 1:8 or 1:10 ratio of tazobactam to piperacillin.
* For example, using the 4.5 g vial (4 g piperacillin / 0.5 g tazobactam):
* A dose of 100 mg/kg/day (piperacillin) would equate to approximately 94 mg/kg/day of the combination.
* **Children ≥ 12 years:** Dosing is the same as adult dosing.
* **Use in neonates and infants < 3 months:** Use is generally not recommended due to lack of established safety and efficacy data, and potential for kernicterus. If used, extreme caution and careful monitoring are required.
## Dose Adjustments
* **Renal Impairment:**
* CrCl > 40 mL/min: No dose adjustment needed.
* CrCl 20-40 mL/min: Reduce maintenance dose by 25% or increase dosing interval to every 8 hours.
* CrCl < 20 mL/min: Reduce maintenance dose by 50% or increase dosing interval to every 6-8 hours.
* Consider administering the full dose after each hemodialysis session.
* **Hepatic Impairment:** No specific dose adjustments are typically recommended, but caution is advised.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillin antibiotics, or cephalosporins.
* History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia.
* **Serious:** Clostridioides difficile-associated diarrhea, hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures (especially with high doses or renal impairment), hematologic abnormalities (neutropenia, thrombocytopenia, eosinophilia, anemia), hepatotoxicity.
## Key Drug Interactions
* **Probenecid:** May increase piperacillin-tazobactam serum concentrations by decreasing renal excretion.
* **Neuromuscular Blocking Agents:** Piperacillin may prolong the action of rocuronium and vecuronium.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance, leading to increased toxicity.
* **Warfarin:** Piperacillin-tazobactam may decrease serum concentrations of warfarin, potentially reducing its anticoagulant effect. Monitor INR closely.
* **Bacteriostatic Antibiotics:** May antagonize the bactericidal effect of piperacillin-tazobactam.
## Monitoring
* Renal function (baseline and periodically during therapy, especially in patients with pre-existing renal disease).
* Liver function tests (baseline and periodically).
* Complete blood count (especially for prolonged therapy).
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of C. difficile infection.
* For patients on warfarin, monitor INR closely.
## Clinical Pearls
* Piperacillin-tazobactam has a broad spectrum of activity, including many gram-positive, gram-negative, and anaerobic organisms, as well as *Pseudomonas aeruginosa*.
* For severe infections or infections with highly resistant organisms, consider higher doses and/or continuous infusion, particularly for *Pseudomonas aeruginosa* or *Enterobacteriaceae*.
* Administer intravenously over at least 30 minutes. For doses ≥ 2 grams, infusion over 30 minutes is recommended. Continuous infusion may reduce the incidence of toxicity and improve efficacy in certain situations.
* When reconstituted, the solution contains approximately 1 mEq of sodium per gram of piperacillin. Use with caution in patients requiring sodium restriction.
***
*This information is intended as a reference and does not replace the need to consult the official prescribing information and current clinical guidelines. Always verify current dosing, indications, and safety information with the product's official labeling and institutional protocols.*
